Drug pricing and market access moved to the centre of pharma regulation in mid-2026, as the focus shifted from registration to money, pricing, financing, and health technology assessment. The US advanced its Medicare price-negotiation framework, Spain opened a consultation on drug pricing, and Portugal formalized a national HTA regime, all in the same month. This is the part of the lifecycle where a perfectly approvable product can still fail commercially, and the gap between approval and access is widening.
The US expanded Medicare drug price negotiation
The Centers for Medicare & Medicaid Services published a proposed rule covering the Medicare Drug Price Negotiation Program and the Medicare Prescription Payment Plan. Price negotiation has reshaped US commercial planning since its introduction, and each expansion widens the set of products, そして mechanics’ manufacturers must model. Pricing strategy, launch sequencing, and lifecycle planning now must account for negotiation exposure rather than treating it as a distant edge case. The companies that adapt earliest build negotiation scenarios into their forecasts; the rest find their assumptions overtaken.
Spain moved on pricing and financing reform
Spain’s Ministry of Health opened a consultation on a draft Royal Decree updating how medicines are priced and financed. Pricing-reform consultations are an opportunity as much as a risk (the window to engage before rules harden), 、 しかし they also signal that the reimbursement bar is being reset. Companies in or approaching the Spanish market should read the draft closely, model the financing implications, and use the consultation period to make their case. Engagement now is far cheaper than repricing after the fact.
ポルトガル established a national HTA framework
Portugal published Decree-Law 118/2026 確立する a national health technology assessment regime, formalizing how new medicines and technologies are evaluated for reimbursement. HTA is increasingly the real gate to access in Europe: approval grants a license, but HTA decides whether the system pays. A formalized framework means earlier, more structured evidence of demands; health-economic data and comparative effectiveness must be planned into development, not assembled at launch when the trial design and comparators are already fixed.
何 this means のために 製薬
Across the US, Spain, and Portugal, the message is consistent: getting approved is no longer the hard part, getting paid is. Bring 市場アクセス thinking forward. Model price-negotiation exposure in the US, engage with pricing consultations like Spain’s while they’re open, and build HTA-grade evidence early for markets formalizing assessment. Access strategy now belongs in development planning alongside the clinical programs, not in the post-approval scramble where evidence of options has already narrowed. RegASK monitors pricing, reimbursement, and HTA developments across global markets, helping regulatory and market-access teams プラン access barriers before launching.
